Osaic Holdings
LVTX

Osaic Holdings’s LAVA Therapeutics LVTX Stock Holding History

Osaic Holdings’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,110
Closed -$1.41K – 7824
2025
Q1 		$1.41K Buy
+1,110
New +$1.24K ﹤0.01% 6710
2023
Q4 		– Sell
-48
Closed -$71 – 7399
2023
Q3 		$71 Hold
48
– – ﹤0.01% 7255
2023
Q2 		$97 Hold
48
– – ﹤0.01% 7290
2023
Q1 		$80 Hold
48
– – ﹤0.01% 7350
2022
Q4 		$0 Hold
48
– – ﹤0.01% 7336
2022
Q3 		$0 Hold
48
– – ﹤0.01% 7411
2022
Q2 		$0 Hold
48
– – ﹤0.01% 7498
2022
Q1 		$0 Hold
48
– – ﹤0.01% 7389
2021
Q4 		$0 Hold
48
– – ﹤0.01% 7491
2021
Q3 		$0 Buy
+48
New +$345 ﹤0.01% 7256

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Osaic Holdings's LVTX Position: Q2 2025 in Review

Osaic Holdings sold out of LAVA Therapeutics (LVTX) in Q2 2025, closing a stake of 1,110 shares — an estimated $1.41K sold.

Osaic Holdings first reported a position in LVTX in Q3 2021 and held it in 10 quarters. The position peaked at $1.41K in Q1 2025. 19 funds tracked by Wall St. Rank hold LVTX as of Q2 2025.

  • Osaic Holdings reported no remaining LAVA Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Osaic Holdings sold 1,110 LAVA Therapeutics shares in Q2 2025, an estimated $1.41K.
  • Osaic Holdings first reported a position in LAVA Therapeutics in Q3 2021 and held it in 10 quarters.
  • Osaic Holdings's LAVA Therapeutics position peaked at $1.41K in Q1 2025.
  • 19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2025.

Based on Osaic Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.